FDA has lifted the clinical hold on vTv Therapeutics' cadisegliatin program, allowing the CATT1 Phase 3 trial for type 1 diabetes to resume after addressing concerns about a chromatographic signal.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.